Vancouver-based Numinus Wellness Inc. has announced a 30-person clinical trial to establish the best practices for treating substance use disorders with psilocybin-assisted psychotherapy.
According to a press release, the trial will be focused on treating tobacco, stimulant, alcohol and opioid disorders.
A 2017 study published in The American Journal of Drug and Alcohol Abuse found that psilocybin-assisted psychotherapy “holds considerable promise” for treating tobacco addiction. After 12 months of psilocybin therapy sessions, roughly 70 per cent of participants had abstained from smoking.